Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neisseria meningitidis Infections - Overview
Neisseria meningitidis Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neisseria meningitidis Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Bioworld Technologies Sdn Bhd
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hilleman Laboratories Pvt Ltd
ImmunoBiology Ltd
Johnson & Johnson
Lanzhou Institute of Biological Products Co Ltd
Neoculi Pty Ltd
Novo Medi Sciences Pvt Ltd
Omvax Inc
Pfizer Inc
ReAlta Life Sciences Inc
Sanofi
Wellstat Vaccines LLC
Neisseria meningitidis Infections - Drug Profiles
(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACYW-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MenBioVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, B, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes C, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [strain C2135] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCL-195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neisseria meningitidis [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06886992 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RLS-0071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neisseria meningitidis Infections - Dormant Projects
Neisseria meningitidis Infections - Discontinued Products
Neisseria meningitidis Infections - Product Development Milestones
Featured News & Press Releases
Sep 17, 2020: Sanofi receives CHMP positive opinion for MenQuadfi intended for prophylaxis against invasive meningococcal disease
Jun 22, 2020: Pfizer announces start of Phase 3 Clinical Trial of MeBCWY
May 29, 2020: The European Medicines Agency has filised its assessment of an application to extend the use of Trumenba for the prevention of invasive meningococcal disease
Aug 29, 2019: $440 million funding boost for vital health and medical research for all stages of life
Nov 28, 2018: NIHR supports world-first trial of new nose drop to fight meningitis
Jun 27, 2018: European approval for lower dose of GSk’s Meningitis vaccine
Jun 18, 2018: New way to determine protection of Men B vaccine against different strains
Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Desigtion for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Cada
Feb 07, 2018: GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Desigtion from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
Dec 13, 2017: Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Data Published In New England Jourl Of Medicine Demonstrate The Vaccine’s Immunogenicity
Nov 22, 2017: Meningococcal Vaccine Antigens expressed by 91 Percent of Tested Bacterial Strains
Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease
Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection
May 30, 2017: European Commission Approves Pfizer’s Trumenba To Help Prevent Meningococcal Group B Disease In Adolescents And Adults
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Neisseria meningitidis Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Neisseria meningitidis Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, H2 2020
Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, H2 2020
Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020
Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H2 2020
Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H2 2020
Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H2 2020
Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, H2 2020
Neisseria meningitidis Infections - Pipeline by Lanzhou Institute of Biological Products Co Ltd, H2 2020
Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, H2 2020
Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, H2 2020
Neisseria meningitidis Infections - Pipeline by Omvax Inc, H2 2020
Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H2 2020
Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, H2 2020
Neisseria meningitidis Infections - Pipeline by Sanofi, H2 2020
Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H2 2020
Neisseria meningitidis Infections - Dormant Projects, H2 2020
Neisseria meningitidis Infections - Dormant Projects, H2 2020 (Contd..1), H2 2020
Neisseria meningitidis Infections - Dormant Projects, H2 2020 (Contd..2), H2 2020
Neisseria meningitidis Infections - Discontinued Products, H2 2020